Ticker brief

JAZZ

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
22
authors 14d
15
crowd 14d
+0.6σ

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-27 · now +0.00 (−1 bearish … +1 bullish)
Who spoke15
authorgradetrader scoresignalsmean sent
@BiopharmIQB·4+0.16
@_TP888C-1.123+0.50
@MartyCharginC-0.272+0.15
@CrweWorldC·2-0.03
@FinanchleC·1-0.45
@markflowchatterB+2.001-0.10
@BPharmCatalystC·1+0.00
@OpenOutcrierC·1+0.30
@cnfinancewatchB-1.921+0.00
@Omnitrader69C-1.391-0.15
@alphaticaioB-1.021+0.80
@AlexMarenco1C-0.281+0.35
@semodoughC-3.011+0.40
@fwpharmaB+0.981+0.50
@spluscollectiveC+0.461+0.50
Recent signals22of 22 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-27@CrweWorld+0.00Jazz priced an upsized exchangeable-notes offering alongside ordinary-share repurchases.·
2026-08-26@MartyChargin-0.15Reports a $1B exchangeable-note offering with a possible $225M share repurchase.·
2026-08-26@CrweWorld-0.05Jazz announces a $1 billion exchangeable-notes offering alongside ordinary-share repurchases.·
2026-08-25@spluscollective+0.50Market recap combines FDA news, earnings reaction and technical signals across four tickers.·
2026-08-25@fwpharma+0.50Ziihera received FDA approval for first-line HER2-positive gastric cancer.·
2026-08-25@BiopharmIQ+0.50FDA approved Ziihera combination regimens as first-line treatment for HER2-positive GEA.·
2026-08-25@semodough+0.40Reports BofA's $307 target and Buy stance after FDA approval of Ziihera in first-line gastric cancer.·
2026-08-25@AlexMarenco1+0.35Flags JAZZ as a stock institutions are buying today, with evidence apparently in the chart.·
2026-08-25@_TP888+0.50Jazz won FDA approval for two advanced gastric-cancer regimens.·
2026-08-25@MartyChargin+0.45Medical stocks are described as finding expected support and bouncing.·
2026-08-25@alphaticaio+0.80Calls JAZZ 65.8% undervalued with a 12-month target of $424.44·
2026-08-25@_TP888+0.50Jazz received FDA approval for two first-line Ziihera-containing regimens.·
2026-08-25@_TP888+0.50FDA approved two Ziihera-containing regimens for advanced HER2-positive gastroesophageal cancer.·
2026-08-24@Omnitrader69-0.15Expresses doubt about JAZZ's ability to complete an unspecified deal.·
2026-08-24@BiopharmIQ+0.25Provides a watch list of four imminent FDA decisions and their investor setups.·
2026-08-23@cnfinancewatch+0.00Lists dated FDA approvals and upcoming PDUFA decisions across a biotech catalyst basket.·
2026-08-21@BiopharmIQ+0.00Reports MRNA's 177% move on positive Phase 3 endpoints and lists upcoming biotech catalysts.·
2026-08-21@OpenOutcrier+0.30Recaps positive and negative chatter and discrete catalysts across six stocks.·
2026-08-21@BPharmCatalyst+0.00Weekly watchlist highlights biotech names with remaining quarterly PDUFA catalysts.·
2026-08-21@markflowchatter-0.10Reports JAZZ and an unnamed $40 billion US biotech as two bidders.·
2026-08-17@Financhle-0.45Reports a $950K aggressive purchase of $240 Jazz puts expiring September 18.·
2026-08-17@BiopharmIQ-0.10Weekly biotech digest reports merger, trial, acquisition and competitive developments across named firms.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.